ABCL
Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
$4.15
+8.64% today
Updated 2026-04-30
Market cap
$1.16B
P/E ratio
—
P/S ratio
15.41x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$2 – $7
Volume
4.1M
Abcellera Biologics Inc (ABCL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-194.90%
Operating margin
-63.70%
ROE
-14.50%
ROA
-9.99%
Debt/equity
0.15x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $8.83M | $309000.00 | 100.00% | -8.53% | 3.50% |
| 2019 | $11.61M | $-2.21M | 100.00% | -35.45% | -19.04% |
| 2020 | $233.16M | $118.92M | 88.36% | 66.92% | 51.00% |
| 2021 | $11.61M | $-2.21M | 100.00% | -35.46% | -19.04% |
| 2022 | $485.42M | $158.52M | 86.31% | 44.60% | 32.66% |
| 2023 | $38.02M | $-146.40M | 100.00% | -623.82% | -385.00% |
| 2024 | $28.83M | $-162.86M | 100.00% | -1,091.69% | -564.83% |
| 2025 | $75.13M | $-146.41M | 100.00% | -288.98% | -194.88% |